These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3091289)

  • 1. Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator.
    Curl GR; Jakubowski JA; Deykin D; Bush HL
    Circulation; 1986 Sep; 74(3 Pt 2):I21-4. PubMed ID: 3091289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of tissue plasminogen activator and urokinase in a canine model of prosthetic graft thrombosis.
    Curl GR; Jakubowski JA; Nabseth DC; Bush HL
    Arch Surg; 1986 Jul; 121(7):782-8. PubMed ID: 3087327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts.
    Comerota AJ; Weaver FA; Hosking JD; Froehlich J; Folander H; Sussman B; Rosenfield K
    Am J Surg; 1996 Aug; 172(2):105-12. PubMed ID: 8795509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of thrombolysis in infrainguinal bypass grafts.
    Sullivan KL; Gardiner GA; Kandarpa K; Bonn J; Shapiro MJ; Carabasi RA; Smullens S; Levin DC
    Circulation; 1991 Feb; 83(2 Suppl):I99-105. PubMed ID: 1991406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulse-spray pharmacomechanical thrombolysis of thrombosed hemodialysis access grafts: long-term experience and comparison of original and current techniques.
    Valji K; Bookstein JJ; Roberts AC; Oglevie SB; Pittman C; O'Neill MP
    AJR Am J Roentgenol; 1995 Jun; 164(6):1495-500; discussion 1501-3. PubMed ID: 7754901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protective effect of heparin in a dog model of rethrombosis following pharmacologic thrombolysis.
    Voytik S; Badylak SF; Burke S; Klabunde RE; Henkin J; Simmons A
    Thromb Haemost; 1990 Nov; 64(3):438-44. PubMed ID: 2128975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts.
    Valentin LI; Sicard GA; Freeman MB; Allen BT; McGoff MA; Anderson CB
    Surgery; 1988 Aug; 104(2):178-84. PubMed ID: 3135624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolysis of occluded infrainguinal bypass grafts.
    Van Damme H; Trotteur G; Dongelinger RF; Limet R
    Acta Chir Belg; 1997 Aug; 97(4):177-83. PubMed ID: 9381900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase therapy for thrombosed hemodialysis access grafts.
    Summers S; Drazan K; Gomes A; Freischlag J
    Surg Gynecol Obstet; 1993 Jun; 176(6):534-8. PubMed ID: 8322124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of in vitro arachidonic acid responsiveness and plasma thromboxane levels with early platelet deposition on the luminal surface of small-diameter grafts.
    Freeman MB; Sicard GA; Valentin LI; Neuberger S; Mangino MJ; Anderson CB
    J Vasc Surg; 1988 Apr; 7(4):554-61. PubMed ID: 3127601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP; Tschopp TB; Kuhn H; Steiner B; Hadváry P
    J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolytic therapy before reconstructive vascular procedures for acute or subacute graft occlusions.
    Sano C; Kumashiro R; Sariego J; Onohara T; Kerstien MD; Matsumoto T
    Int Surg; 1993; 78(1):50-3. PubMed ID: 8473085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolysis with recombinant human tissue-type plasminogen activator in patients with peripheral artery and bypass graft occlusions.
    Graor RA; Risius B; Lucas FV; Young JR; Ruschhaupt WF; Beven EG; Grossbard EB
    Circulation; 1986 Sep; 74(3 Pt 2):I15-20. PubMed ID: 3091288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulsed-spray thrombolysis of arterial and bypass graft occlusions.
    Valji K; Roberts AC; Davis GB; Bookstein JJ
    AJR Am J Roentgenol; 1991 Mar; 156(3):617-21. PubMed ID: 1825256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of platelet deposition and neointimal hyperplasia of heparin-coated small-caliber ePTFE grafts in a canine femoral artery bypass model.
    Lin PH; Bush RL; Yao Q; Lumsden AB; Chen C
    J Surg Res; 2004 May; 118(1):45-52. PubMed ID: 15093716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental femoral vein reconstruction with expanded polytetrafluoroethylene grafts seeded with endothelial cells.
    Li JM; Menconi MJ; Wheeler HB; Rohrer MJ; Anderson FA; Cutler BS
    Cardiovasc Surg; 1993 Aug; 1(4):362-8. PubMed ID: 8076060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
    Hong TT; Driscoll EM; White AJ; Sherigill A; Giboulot TA; Lucchesi BR
    J Pharmacol Exp Ther; 2003 Aug; 306(2):616-23. PubMed ID: 12734394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
    J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.